

Colorpak Limited

14 December 2011

Valuation and key data:

ASX code	CKL
Share price (cps)	68
Valuation (cps)	83
Prem/(Disc) to price	22%
Shares on issue (m)	81.2
Market Cap. (\$m)	55.2
12mth price range (cps)	60 - 76


Summary Financials:

June Y/E	11a	12e	13e
Rev. (\$m)	127.4	207.0	208.8
change	58%	62%	1%
NPAT (\$m)	7.1	7.7	8.4
change	10%	9%	8%
EPS (cps)	8.7	9.5	10.2
change	10%	9%	8%
DPS (cps)	3.3	3.3	3.5
Tangible ROE	48%	31%	31%

Valuation multiples:

PER(x)	7.8	7.2	6.7
Div. Yield	4.8%	4.8%	5.2%
EV(\$m)	89.4	100.2	98.5
EV/EBIT (x)	6.0	6.2	5.8

Abs. & Rel. Share Price Performance



Source: IRESS

Key points

We value Colorpak Limited (CKL) at 83 cps, up 22% from the current share price of 68 cps. The 83 cps valuation implies a 12 mth forward PER of 8.5x and EV/EBIT of 6.8x. Both these valuation multiples are c.85% of the respective Small Industrial's averages.

CKL provides investors with defensive revenues and profits as well as the potential for growth.

Defensive revenues and profits

Since 2003, revenues from the folding carton industry have remained largely unchanged (local production) despite the GFC (c.\$612m-c.\$623m). The steady nature of industry revenue is a result of the non cyclical nature of the packaged products which CKL's customers offer (eg, pharmaceutical, food, fast food, beverages).

Despite steady 'top line' industry conditions, an impressive feature of CKL is that it has **achieved increases in market share** (prior to the Carter Holt Harvey (CHH) acquisition) **yet maintained its profit margins**. CKL's revenue has increased from c.\$48m in FY02 to c.\$85m in FY11 whilst increasing its EBIT margin from 12.1% in FY06 to 14.9% in FY11. CKL has also built a track record for acquiring complimentary businesses (6 in 12 yrs) although the purchase of CHH was a transformational event taking the company to revenues of c.\$207m p.a.

Growth options

The main growth option for the company is achieving economic returns from the recently acquired CHH business. The achievement of a conservative FY14e EBITDA margin of c.5.3% for the acquired CHH business produces incremental EBITDA of c.\$6m, **which represents 40% growth from the \$15.0m achieved by the traditional CKL business in FY11a.**

Operational and valuation comps with international peers

Relative to international peers, CKL's gross returns (ie revenue/tangible assets) are at the upper end of the range, and net returns (ie NPAT/tangibles assets) are similar. **The largest variance is CKL trades at a c.30-40% valuation discount to its larger international peers.**

Sensitivities

There are a number of key sensitivities (listed in this report) but the key determinant of future profit and valuation is EBITDA margins from the acquired CHH revenue streams.

The 83 cps valuation of CKL includes a FY14e EBITDA margin of c.5.3%. The upside case is 7%+ EBITDA margins, which if achieved without material revenue attrition will increase the valuation to c.105+ cps. If CHH continues to achieve virtually no profit, the CKL valuation declines to c.57 cps.

To date, the integration of CHH is progressing well and to plan.

Contents	Page(s)
Company Overview	3 - 5
Industry Overview	6 - 7
Carter Holt Harvey Acquisition	8 - 11
Income Statement	12
Cashflow	13
Balance Sheet	14
Appendices:	
- Financial and Valuation Summary	16
- Financials	17
- Main Sensitivities	18
- Valuation Observations	19
- Directors	20
- International Peer Comparisons	21-24

Company Overview

Picture: Location of CKL's business operations



Source: CKL presentation


CKL designs and produces folding cartons, self adhesive labels, leaflets, printed and plain hard tempered aluminium foil, sachets, paper cups (new) and point-of-sale displays and other value-added paperboard packaging products. CKL listed on ASX in 2004 and now has c.770 staff.

CKL has acquired and integrated 6 businesses since 1998:

- 1998 – Foilmasters (Victoria)
- 2000 – Hale Foldpack (NSW)
- 2001 – Pemara Packaging (Victoria)
- 2004 – Castle Graphics (NSW)
- 2010 – Remedies printing business (NSW)
- 2011 – Carter Holt Harvey Cartons (NSW, Victoria & NZ)


Following the acquisition of CHH, CKL is expected to achieve annualised revenues of c.\$207m and operates 5 manufacturing sites in Melbourne (2), Sydney (2) and Auckland (1) and has a sales office in Brisbane.

Picture: CKL Proforma Revenue post CHH acquisition



Source: CKL presentation

Chart: Revenue by market segment (FY11a)



Source: CKL presentation


The stability and growth of CKL’s revenue (illustrated on the previous page) since 2002 is impressive. It is an indication of the non-cyclical nature of demand for CKL’s services and products as well as good management. Typically, customers enter 1-3 year contracts with CKL.

CKL sources its paperboard from Amcor’s Petrie Board Mill, the CHH Pulp & Paper Whakatane Mill in NZ, the US for its beverage customers and from Australian board merchants. The paper board industry is competitive and although raw material prices can vary, customer contracts typically allow CKL to pass on price increases in raw material.

CKL is the market leader with substantial market share in the pharmaceutical packaging sub segment of the folding cartons industry. This is a premium product with high barriers to entry. Growth is driven by new products, an aging population and legislation.

The main components of CKL’s folding carton production process are illustrated below and discussed on the following page.

Picture: Production Process




Source: CKL Prospectus

CKL uses predominantly European machines which are superior to Asian alternatives and offers an integrated solution from design to shipping.

- **Structural and Graphic Design.** CKL design team works with customers to create packaging solutions that meet customer's marketing and in some cases meet regulatory requirements.
- **Pre-Press.** Ensures that the graphic design is compatible with the structural design template. A proof is produced for approval.
- **Printing.** Core capability is sheet fed lithographic offset printing and flexographic reel fed printing. Multiple techniques and finishing's are available and CKL is the exclusive member of the Waterless Printing Association.
- **Cutting, Folding and Gluing.** Machine accuracy and consistency are paramount to achieve required creaseability and functionality.
- **Embossing and Foil Stamping.** Offered under CKL's Foilmasters brand
- **Other specialised packaging options.** For eg, tamper-evident designs, binary code verification, insertion and folding of leaflets...
- **Shipping.** Shipped flat to customer's premises.

Industry Overview

Chart: Folding carton industry revenue estimate (local production only)




Source: Industry data and estimates

The Australian folding carton industry revenue is c.\$620m (local production) and is segment of the \$3.2bn paper and board packaging industry. **The industry is mature** and is primarily characterised by:

- Steady revenue @ c.\$612m-c.\$623m since 2003
- An increase in imported paper board product, however, this has slowed since FY10 and may slow further with a lower AUD.
- Production processes subject to technological advancement which improves productivity and quality, and
- Customers demanding reliable service & product supply at lower cost.

An estimate of the market shares of the Australian folding carton industry are illustrated below. CKL and Amcor are now the industry leaders with market shares of c.31% each. The remaining participants have market shares of c.10% or less and include Visy, ANZPAC, HannaPack, Abaris.

Picture: Market share of the Australia folding carton industry



Source: CKL investor presentation

The folding carton industry can be divided into two main components:

- The 'short-run' market that produces higher quality packaging for consumer products such as pharmaceuticals, cosmetics, medicines, technology and increasingly, premium food products.
- The 'long-run' market that produces higher volumes of product with less sophistication and is mostly the fast moving consumer goods such as fast food, beer, cereal and other food products.

It is expected that consolidation of the folding carton industry will continue in order to:

- Restore rational pricing. Margins, ROE and ROA in the market have declined to levels which are uneconomic. Rationale pricing is required to enable reinvestment.
- Increase volumes to reduce unit costs and drive other efficiencies.
- Requires scale to service national and international accounts.

CHH (pre CKL) and Amcor mainly focus on the 'long run' market and over many years competed aggressively on price. CHH (pre CKL) is thought to be responsible for most of the recent price discounting as evident in the lack of profit when CKL acquired the business. For the 4 months to 30/6/11, CHH under CKL ownership achieved profit of \$0.4m from \$40.9m of revenue.

Both CHH (pre CKL) and Amcor provided demand for their upstream paperboard manufacturing facilities, being Amcor's Petrie Board Mill and CHH Pulp & Paper Whakatane Mill in NZ. These assets are highly capital intensive and require high utilisation rates to cover fixed costs. CKL does not have upstream manufacturing operations but the paperboard market is globally competitive.

The main barriers to entry include:

- Customer relationships which are only established over long periods of reliable service and product supply. CKL's main point of differentiation is its clean processing conditions which meet the demands of the food and pharmaceutical sectors.
- Capital intensity due to expensive machines, and
- Technically demanding design and production processes.

Carter Holt Harvey acquisition

Headline financial estimates

The addition of CHH (excluding the Smithfield business) should add c.\$119m of revenue and c.\$4m of EBITDA to CKL in FY12e

Table: CHH headline financials

	12 mths to 31/12/09	4 mths to 30/6/11	FY12e	FY13e	FY14e	FY15e
Revenue	170.0 ⁽¹⁾	40.9	118.8	118.8	118.9	118.8
EBITDA	4.0 ⁽²⁾	0.8	3.6	5.2	6.3	6.9
EBITDA margin		2.0%	3.1%	4.3%	5.3%	5.8%
EBIT		0.4	2.6	3.8	4.6	5.0
EBIT margin		1.0%	2.2%	3.2%	3.9%	4.2%

Note: (1) includes Smithfield; (2) 'in CKL hands'. CHH was broadly break even at acquisition.

Source: CKL reports and estimates

Background

In December 2010, CKL announced the acquisition of the folding carton businesses of Carter Holt Harvey (CHH) conducted at Reservoir and Mount Waverley in Victoria, Villawood in NSW and Auckland in NZ. CHH also operated a business in Smithfield NSW but this was acquired by Amcor. The acquisition included Montage Solutions which provides pre-press and structural design services to the CHH carton and corrugated businesses as well as the trade.

Completion of the acquisition was achieved on 1st March 2011 and CKL's FY11 result included a 4 month contribution from CHH. CHH was effectively break even at acquisition primarily due to CHH's strategy of competing aggressively on price.

As part of the acquisition, CKL is mandated until March 2013 to acquire folding carton board in respect of the acquired CHH businesses in both Australia and NZ on competitive terms from the Reynolds Group's Whakatane Mill.

Strategic Rationale

The strategic rationale for the acquisition was:

- Extension of customer offering throughout both Australia and NZ;
- Greater manufacturing capabilities;
- Increased relevance to suppliers as a result of greater scale;
- Broader customer base, and
- Financial benefits (examined below).

Financial benefits

We estimate the pre tax IRR on the acquisition will be c.20%, and the FY13e and FY14e proforma EV/EBIT multiples will be < 6.6x and 5.4x respectively.

Table: Net Cashflows, pre tax IRR and acquisition valuation multiples

	FY11a	FY12e	FY13e	FY14e	FY15e	...
CHH EBIT	0.4	2.6	3.8	4.6	5.0	
EBITDA margin		3.1%	4.3%	5.3%	5.8%	
EBIT margin		2.2%	3.2%	3.9%	4.2%	
CHH acquisitions costs:						
Cash payment for base bus.	-5.0					
Transaction costs	-1.4					
Integration costs	-2.2	-10.0				
Working capital adj's ⁽¹⁾		-4.3				
Unwind of Provisions ⁽²⁾		-1.0	-0.9	-1.5	-0.9	
Total costs	-8.6	-15.3	-0.9	-1.5	-0.9	
Net Cashflows	-8.2	-12.7	2.9	3.2	4.1	
Pretax IRR ^{(1) & (2) & (3)}	19%					
NPV of total costs ⁽³⁾	-25.1					
Proforma EV/EBIT		9.7	6.6	5.4	5.0	

Note: (1) this figure does not reflect any benefit from an improvement in working capital over time; **(2)** Upon acquisition of CHH, CKL took on \$16.5m in liabilities including lease rentals that are not considered to be commercial in the current market as well as make good obligations under those premises leases and also some contracts with customers that were considered to be uneconomic. These figures do not reflect any benefits from actions such as sub leasing; **(3)** 2.5% long term growth; **(4)** discounted at 9.5%, being CKL's cost of debt. **Source:** CKL reports and estimates

CHH acquisition and integration costs

As illustrated in the table above, consideration for CHH comprises many components:

- \$5m upfront payment in FY11a;
- \$1.4m of various acquisition related transaction costs in FY11a;
- \$2.2m integration costs in FY11a;
- c.\$6.7m of staff redundancy in FY12e. There was a net reduction of c.33 staff but redundancy has been offered to c.90 staff and c.57 new staff have been hired;
- c.\$1.3 of premise relocation and other related in FY12e. Three production sites in Victoria rationalised to two, as well as expanding the Braeside site, and
- c.\$2.0m for payout of leave entitlements in FY12e.

These are summarised in the table below.

Table: CHH acquisition and integration costs

\$m	FY11a	FY12e
Various acquisition related transaction costs	1.4	
Integration costs	2.2	
Staff redundancy costs		6.7
Premise relocation and other		1.3
Payout of lease entitlements		2.0
Total	3.6	10.0

Source: CKL reports

CKL reports that the CHH integration is progressing well:

- Major customer engagement process largely complete and all major accounts met.
- Internal and external brand launches completed with formal events with strong customer engagement.
- New brand collateral working way through all sites.
- New IT program progressing well with first of 3 sites live on 1/9/11.
- Cost synergies identified and being delivered in a timely manner.

The upside case

Our earnings estimates include the acquired CHH business achieving an EBITDA margin of c.5.3% in FY14e. There is upside potential to this estimate. Below we illustrate the IRR and acquisition valuation multiples if CKL achieves a 7.2% EBITDA margin from the acquired CHH revenues.

The pre tax IRR from the CHH acquisition increases to c.28% and the proforma EV/EBIT multiples falls materially to c.3.6x in FY14e.

Table: Upside case (Net Cashflows, IRR and acquisition valn multiples)


	FY11a	FY12e	FY13e	FY14e	FY15e	...
CHH EBIT	0.4	2.6	5.7	7.0	7.5	
EBITDA margin		3.4%	5.9%	7.2%	7.9%	
EBIT margin		2.2%	4.8%	5.9%	6.3%	
CHH acquisitions costs:						
Cash payment for base bus.	-5.0					
Transaction costs	-1.4					
Trans. related integration act's	-2.2	-10.0				
Working capital adj's ⁽¹⁾		-4.3				
Unwind of Provisions ⁽²⁾		-1.0	-0.9	-1.5	-0.9	
Total costs	-8.6	-15.3	-0.9	-1.5	-0.9	
Net Cashflows	-8.2	-12.7	4.8	5.5	6.6	
Pretax IRR ^{(1) & (2) & (3)}	28%					
NPV of total costs ⁽⁴⁾	-25.1					
Proforma EV/EBIT		9.7	4.4	3.6	3.4	

Note: (1) this figure does not reflect any benefit from an improvement in working capital over time; **(2)** Upon acquisition of CHH, CKL took on \$16.5m in liabilities including lease rentals that are not considered to be commercial in the current market as well as make good obligations under those premises leases and also some contracts with were customers that considered to be uneconomic. These figures do not reflect any benefits from actions such as sub leasing; **(3)** 2.5% long term growth; **(4)** discounted at 9.5%, being CKL's cost of debt. **Source:** CKL reports and estimates.

Diversification

A major strategic benefit from the acquisition of CHH is it has significantly broadened CKL's customer base. This is illustrated in the chart below.

Chart: Diversification of revenue following CHH acquisitions



Source: CKL reports and estimates

Pre the CHH acquisition, CKL derived c.45% of its revenue from the pharmaceutical / healthcare industry segment. Three customers each contributed revenues > 10% of total revenue and which aggregated to 41% of revenues.

Post the CHH acquisition, the pharmaceutical / healthcare industry segment contributes c.27%. CKL has a single customer that contributes revenues > 10% of the group's revenues (being 15%). The top 3 customers now contribute a little over 20% of total revenue. The table below provides examples of customers by segment and some comments on each segment.


Table: Revenue, Examples of Customers and comments by market segment

Market Segments	Revenue		Examples of Customers	Comments
	Old CKL ⁽¹⁾	New CKL ⁽²⁾		
\$m			Industry	
Pharmaceutical /Healthcare	35	58	AstraZeneca, Pfizer, GSK	Premium product, high barriers to entry, growth driven by new product launches, an aging population and legislation.
Beverage	15	41	Graphic Packaging	Lower margin but has been growing.
Food	14	52	McCains, Nestle, Goodman Fielder	Commoditised with some low margin volumes moving offshore.
Fast Food	-	13	McDonalds, Pizza Hut, KFC	Has been achieving good growth since GFC due to consumers looking for more affordable and convenient options.
FMCG	10	21	Cussons, Ingham, Kraft	High volume & continual product development.
Cosmetics	2	4	L'Oreal, Jurlique	Premium product.
Other	5	18	Telstra, MYOB	Environmental leaders
Total	\$81m	\$207m	c.\$630m	

Notes: (1) FY10a reported by CKL; (2) FY12e. **Source:** CKL reports, Industry data and estimates.

Income Statement

Chart: Revenue and EBIT (CKL & CHH)




Source: CKL reports and estimates

The most impressive aspect of CKL's historical financial results has been the maintenance of margins, unlike many of its competitors. Between FY06a and FY11a, CKL's EBIT margins have ranged between 12.1% and 14.9%. This is predominantly due to management's discipline with customer pricing, including its ability to pass-on increases in board prices to customers.

Raw materials and staff expenses comprise the vast majority (c.85%) of CKL's expenses. Between FY06a and FY11a, raw material and staff expenses consistently represented c.40% and c.30% of revenue respectively. This will change with the addition of the lower margin CHH business which reported profit of only \$0.4m for the 4 months to 30/6/11.

The acquisition of CHH shall increase CKL's revenue to c.\$207m in FY12e (CKL @ c.\$88m + CHH @ \$119m). A small improvement in CHH's EBIT margins will lead to large increases in group EBIT.


Chart: EBIT margins



Source: CKL reports and estimates

Cashflow

Chart: Capex




Source: CKL reports and estimates

FY11 capex was \$5.58m, the main item of expenditure being a cup and lid forming machine at the Braeside manufacturing site. CKL has provided guidance that FY12e capex will be c.\$6m. The D&A charge is expected to increase from \$3.1m in FY11a to \$4.3m in FY12e, which indicates Free Cash Flow will be c.\$2m below NPAT before a number of 'one offs' including:

- A payment of \$4.3m for working capital adjustments in respect of the CHH acquisition, and
- One off integration costs of c.\$8m + leave entitlement payouts of c.\$2m.
- c.\$3m for the unwind of unfavourable customer contracts and leases. We estimate the unwind will continue for c.5 years at c.\$2-3m p.a.

FY11 cashflows were adversely impacted by the delay of a single payment of \$2.08m which was received on 1st July 2011, so FY12 will see a boost to cash from operations.


Chart: Rep. EBITDA vs Cash receipts less payments



Source: CKL reports and estimates

Balance Sheet

Chart: Assets




Source: CKL reports and estimates

There are three major balance sheet items of note:

- The \$46.1m of goodwill which is a result of the accounting treatment and structure adopted at the time of listing in 2004. None of the acquisitions since listing have added to goodwill.
- Gearing. Debt increased from \$22.8m @ 30/6/10 to \$34.3m @ 30/6/11, and is expected to increase further to c.\$43m at 30/6/12.
- Increased provisions in relation to the CHH acquisition. CKL took on \$16.5m in liabilities including lease rentals that are not considered to be commercial in the current market as well as make good obligations under those premises leases and also some contracts with customers that are considered to be uneconomic.

The FY12e book ROE and ROA is low at 11.8% and 5% but excluding the \$46.1m of goodwill, tangible ROE and ROA increases to 32% and 7% respectively. Loan facilities are provided by NAB and BNZ and the bank bill facilities expire on 1/9/13, the trade finance loan facility on 30/4/14 and other bank facilities on 31/8/12. All debt facilities are expected to be renewed.

Table: Net Debt & Gearing (Debt / (Debt + Equity))



Source: CKL reports and estimates

Appendices

Financial and Valuation Summary

Valuation & Investment Data									
ASX code	CKL								
Share price (cps)	68								
DCF valuation (cps)	83								
Premium/(Discount) to price	23%								
Shares on issue (m)	81.2								
Market Capitalisation (\$m)	55.2								
12mth share price range (cps)	60 - 76								

Headline Financials (June Y/E)	FY06a	FY07a	FY08a	FY09a	FY10a	FY11a	FY12e	FY13e	FY14e
Revenue (\$m)	70.7	71.8	78.8	78.8	80.8	127.4	207.0	208.8	210.7
<i>change</i>		2%	10%	0%	3%	58%	62%	1%	1%
EBITDA (\$m)	10.9	12.7	14.3	13.5	14.6	15.8	19.1	20.8	22.2
<i>change</i>		17%	13%	-6%	8%	9%	21%	9%	7%
EBIT (\$m)	8.5	9.8	11.5	10.5	11.6	12.7	14.8	16.2	17.1
<i>change</i>		15%	17%	-9%	11%	9%	17%	9%	6%
NPAT (\$m)	4.5	5.1	6.2	5.6	6.4	7.1	7.7	8.4	9.2
<i>change</i>		12%	23%	-10%	14%	10%	9%	8%	10%
EPS (cps)	5.6	6.3	7.7	6.9	7.9	8.7	9.5	10.2	11.2
<i>change</i>		12%	23%	-10%	14%	10%	9%	8%	10%
DPS (cps)	2.75	2.75	3.00	3.00	3.25	3.3	3.3	3.5	3.84
Franking	100%	100%	100%	100%	100%	100%	100%	100%	100%
Tangible ROE		228%	111%	65%	57%	48%	31%	31%	29%

Valuation multiples									
PER (x)						7.8	7.2	6.7	6.1
Div. Yield						4.8%	4.8%	5.2%	5.6%
Enterprise value (\$m)						89.4	100.2	98.5	95.7
EV/EBITDA (x)						4.7	4.8	4.4	
EV/EBIT (x)						6.0	6.2	5.8	

Financials

INCOME STATEMENT	FY10a	FY11a	FY12e	FY13e	FY14e
Revenue	80.8	127.4	207.0	208.8	210.7
Expenses	-66.3	-111.6	-187.9	-188.0	-188.5
EBITDA	14.6	15.8	19.1	20.8	22.2
D&A	-3.0	-3.1	-4.3	-4.7	-5.1
EBIT	11.6	12.7	14.8	16.2	17.1
Net Interest inc./exp.	-2.5	-2.5	-3.8	-4.2	-4.0
Pretax Profit	9.1	10.2	11.0	11.9	13.1
Tax	-2.7	-3.2	-3.3	-3.6	-3.9
OEI	0.0	0.0	0.0	0.0	0.0
Adj NPAT	6.4	7.1	7.7	8.4	9.2
add/(less): sig. items (a/tax)	0.0	8.8	-7.0	0.0	0.0
Rep. NPAT	6.4	15.9	0.7	8.4	9.2

CASHFLOW	FY10a	FY11a	FY12e	FY13e	FY14e
Rec's less pay's	12.3	11.4	8.0	18.3	19.5
Interest inc.	0.0	0.1	0.0	0.0	0.0
Interest exp.	-2.3	-2.6	-3.8	-4.2	-4.0
Tax	-1.0	-2.6	-3.1	-3.5	-3.8
Other	0.0	0.0	0.0	0.0	0.0
Operating cashflows	9.0	6.2	1.1	10.6	11.7
Capex	-1.2	-5.7	-5.0	-6.0	-6.0
Acq./sale of bus.'s	0.0	-8.6	-4.3	0.0	0.0
Other	0.0	0.2	0.0	0.0	0.0
Investing cashflows	-1.2	-14.2	-9.3	-6.0	-6.0
Equity	0.0	0.0	0.0	0.0	0.0
Debt	-4.8	8.3	12.0	-2.0	-2.0
Dividends	-2.6	-3.4	-2.7	-2.8	-3.0
Other	0.0	0.0	0.0	0.0	0.0
Financing cashflows	-7.4	4.8	9.3	-4.8	-5.0
Change in cash	0.4	-3.2	1.2	-0.2	0.7
Cash (EoP)	0.0	-3.2	-2.0	-2.2	-1.5

CAPITAL	FY10a	FY11a	FY12e	FY13e	FY14e
Equity	39.2	39.5	39.5	39.5	39.5
Reserves	-0.6	-0.4	-0.4	-0.4	-0.4
Retained earnings	21.8	34.2	32.3	37.8	43.8
Minorities	0.0	0.0	0.0	0.0	0.0
Shareholders equity	60.5	73.3	71.3	76.8	82.9
Represented by:					
Cash	0.0	0.0	0.0	0.0	0.0
Receivables	12.6	38.2	39.1	39.4	39.8
Inventories	10.2	30.5	30.8	31.1	31.4
Other	0.6	1.8	1.8	1.8	1.8
Current assets	23.5	70.5	71.7	72.3	72.9
PPE	27.9	40.6	41.3	42.7	43.7
Intangibles	46.1	46.1	46.1	46.1	46.1
Other	0.0	3.8	3.8	3.8	3.8
Non current assets	74.0	90.6	91.3	92.7	93.6
Total assets	97.5	161.1	163.0	165.0	166.6
Payables	8.6	25.4	27.8	28.0	28.2
Debt	0.0	3.2	2.0	2.2	1.5
Other	2.5	13.6	7.0	8.2	7.8
Current liabilities	11.1	42.2	36.8	38.4	37.6
Debt	22.8	31.0	43.0	41.0	39.0
Other	3.1	14.6	11.9	8.8	7.1
Non current liabilities	25.9	45.6	54.9	49.8	46.1
Total liabilities	37.0	87.8	91.7	88.2	83.7
Net assets	60.4	73.3	71.3	76.8	82.9
Net Tangible Assets	14.3	27.1	25.2	30.7	36.7

Main Sensitivities


- **Margins.** Although CKL has been able to hold its EBITDA margins over many years, margin pressure is a threat. As discussed in this report, CKL is expected to benefit from achieving economic margins from the acquired CHH business and this is the main sensitivity for CKL's future profits and valuation.

We derive a 83 cps valuation for CKL which includes a c.5.3% EBITDA margin in FY14e.

If the contribution from CHH continues to be close to 0, the CKL valuation declines to c.57 cps.

If the contribution from CHH increases to reflect an EBITDA margin of c.7%, then the CKL valuation increases to c.105 cps


Chart: CKL Valuation vs CHH EBITDA margin



Source: CKL reports and estimates

- **Customers.** Although the acquisition of CHH's folding carton business has significantly diversified CKL's customer base, CKL has a number of large customers which if lost would impact future profits.
- **Raw materials.** The folding carton industry is supplied with paperboard by local producers and imports through local paper merchants. Whilst supply shortages are uncommon, raw material prices are subject to fluctuations. Since FY05, CKL has successfully retained raw material costs as a proportion of revenue at c.39% - 43% as illustrated below left.

Chart: CKL raw material costs/Revenue




Source: CKL reports

- **Imported product.** The proportion of imported product has increased to c.9% of total industry revenue, which is a threat to local producers. However, this has not changed materially since 2009. The recent depreciation of the AUD should act as a deterrent for customers considering importing product.


Valuation Observations

Chart: 12 month forward PER




Source: Reported and estimates

Chart: EV/EBIT




Source: Reported and estimates

Chart: Free Cash Flow Yield vs 3 mth BB Swap




Source: Reported and estimates

Chart: PER relative to ASX 100




Source: Companies and estimates

Chart: EV/EBIT relative to ASX 100



Source: Companies and estimates

Chart: Small Ind. PER vs ASX 100 PER



Source: Companies and estimates

Directors

- **Geoff Willis, Chairman** of CKL since January 2004. Mr Willis was the CEO of Hydro Tasmania from 1999 to 2006, and prior to that appointment he was a member of the Amcor senior management team from 1982 to 1998. Geoff is currently the Chairman of Aurora Energy Pty Ltd, Chairman of the Tasmanian Symphony Orchestra and a Trustee of the Tasmanian Museum and Art Gallery.
- **Alex Commins, Managing Director.** Mr Commins joined CKL in 1992 after starting his career in auditing and accounting. Mr Commins has been the Managing Director since January 2003 and maintains direct responsibility for CKL's strategy development, customer relationships. Mr Commins is a board member of the Victoria Chapter of the French Australian Chamber of Commerce and Industry.
- **Paul Commins, Executive Director.** Mr Commins joined CKL in 1993 after managing his own screen printing business. Mr Commins implemented the ISO 9001:2000 quality standard and played a key role in the integration of Pemara Corporation's folding carton division into CKL's Braeside operations in 2001. Between 1999 and 2002, Mr Commins was Managing Director of CKL. Mr Commins' primary focus is seeking productivity efficiencies for the business by the adoption of new technologies.
- **Ms Bronwyn Constance, Non-executive Director.** The early part of her career was spent with the ACI Group of companies, followed by senior financial roles with Kraft Foods Ltd in Australia and Asia, CFO of Pasmenco Ltd and Finance Director of Nylex Ltd. Currently she is a director and chairs the audit committees of The Melbourne Market Authority and the Co-operative Research Centre for Advanced Automotive Technology.
- **David Heaney, Non-executive Director.** Mr Heaney joined CKL in January 2004 and has vast experience in banking and corporate finance gained with the National Australia Bank and subsidiary companies, where he held several senior management positions in Australia and the United States. Mr Heaney also serves as a director of the listed companies, Cyclopharm Limited and Dromana Estate Limited.
- **Ian Wightwick, Non-executive Director.** Until his retirement from full time employment in February 2004, Mr Wightwick was Managing Director and Chief Executive Officer of PaperlinX, which was demerged from Amcor, and listed on the ASX under his stewardship in 2000. PaperlinX grew by acquisition to be the largest international paper merchant, also having substantial paper manufacturing operations in Australia. Prior to PaperlinX, Mr Wightwick filled various executive marketing and divisional Managing Director roles in Amcor.
- **Mr Harry Commins, Alternate Director.** Mr Commins is CKL's National Manufacturing Director and is an alternate director for Paul Commins. Mr Commins joined CKL in 1992 after starting his career with a large printing company. Mr Commins oversees production, maintenance, crewing levels, and is a key driver on the Quality Assurance and Occupational Health and Safety committees. He plays a major role in CKL's assessment and development of new technologies. Mr Commins is also an integral part of the sales team in a technical capacity with new product development, promotional activities and as co-ordinator of capacity utilisation between the plants.

International peers

Company Name, Code, EV (US\$m) and Company Description

Company Name	Code	EV (US\$m)	Company description
Mayr-Melnhof Karton AG	MMK-AT	1,104	MMK engages in the manufacture and sale of cartonboard and folding cartons in Europe. It operates through the Mayr-Melnhof Cartonboard (MM Karton) and Mayr-Melnhof Packaging (MM Packaging) segments. MM Karton manufactures and markets numerous grades of cartonboard, concentrating on coated cartonboard produced predominantly from recycled paper.
CCL Industries Inc. (CI B)	CCL.B-CA	1,265	CCL provides specialty packaging and labeling solutions for the consumer products and healthcare industries. The company also provides packaging solutions to the Home & Personal Care, Premium Food & Beverage, Healthcare and Specialty markets worldwide.
Cascades Inc.	CAS-CA	1,909	CAS manufactures and markets packaging & tissue products composed of recycled fibres. It offers coated boxboard, containerboard, folding cartons and convert tissue paper for the commercial, institutional and retail markets. It has operations in North America and Europe.
Graphic Packaging Holding Co.	GPK-US	3,878	GPK provides paperboard packaging solutions for various products to multinational food, beverage, and other consumer products companies. The company also produce bags, labels, inks, coatings, flexible and specialty packaging, as well as paperboard grades, packaging machinery, and services.
Sonoco Products Co.	SON-US	3,898	SON manufactures industrial and consumer packaging products and provides packaging services. The company operates through two segments: Tubes and Cores/Paper and Consumer Packaging.
Rock-Tenn Co. CI A	RKT-US	6,306	RKT manufactures packaging products, recycled paperboard, containerboard, bleached paperboard and merchandising displays. The company operates through four segments: Consumer Packaging, Corrugated Packaging, Merchandising Displays and Specialty Paperboard Products.
MeadWestvaco Corp.	MWV-US	6,557	MWV is a packaging company which provides packaging solutions to many of brands in the healthcare, beauty and personal care, food, beverage, tobacco and home and garden industries.
Klabin S/A ADS	KLBY-US	8,816	KLBY engages in manufacturing, selling, and distributing paper to the internal and external market. It produces, exports, and recycles paper in Brazil. It also manufactures cardboards, corrugated boxes, industrial sacks, envelopes, wood, pulp for paper production, dissolving pulp and tissue.

Appendix – International peers

Comparison of Gross Returns ⁽¹⁾, Efficiency ⁽²⁾ and Net Returns ⁽³⁾

Coy Code	Gross Return (1)		Efficiency (2)		Net Return (3)	
	FY11a/e	FY12e	FY11a/e	FY12e	FY11a/e	FY12e
MMK-AT	126%	122%	13%	13%	8%	8%
CCL.B-CA	97%	101%	19%	19%	7%	7%
CAS-CA	101%	107%	7%	9%	0%	1%
GPK-US	120%	125%	14%	15%	4%	5%
SON-US	156%	164%	12%	13%	9%	9%
RKT-US	62%	110%	14%	15%	2%	5%
MWV-US	68%	69%	17%	18%	4%	4%
Median	101%	110%	14%	15%	4%	5%
CKL (FY12e/FY13e)	169%	168%	9%	11%	6%	8%
Variance	68%	53%	-33%	-29%	56%	40%

Notes: (1) Revenue/Tangible Assets; (2) EBITDA margins; (3) NPAT/Tangible Assets

Source: Factset, CKL reports and estimates

Appendix – International peers

Comparison of Reinvestment ⁽¹⁾, Revenue growth and EPS growth

Coy Code	Re-investment (1)		Revenue growth		EPS growth	
	FY11a/e	FY12e	FY11a/e	FY12e	FY11a/e	FY12e
MMK-AT	7.8%	5.9%	10%	0%	8%	3%
CCL.B-CA	6.3%	6.6%	5%	4%	16%	12%
CAS-CA	3.8%	3.4%	2%	-6%	-42%	-93%
GPK-US	3.7%	4.7%	0%	2%	633%	45%
SON-US	6.0%	5.1%	15%	10%	31%	4%
RKT-US	4.9%	2.3%	80%	79%	-5%	24%
MWV-US	2.7%	8.1%	-6%	6%	97%	32%
Median	4.9%	5.1%	4.8%	4.4%	16%	12%
CKL (FY12e/FY13e)	2.4%	5.0%	nm	nm	5%	24%
Variance	-51%	-3%	nm	nm	nm	nm

Notes: (1) Capex / Tangible Assets

Source: Factset, CKL reports and estimates

Appendix – International peers

Valuation comparison

Coy Code	EV/EBITDA		EV/EBIT		PER	
	FY11a/e	FY12e	FY11a/e	FY12e	FY11a/e	FY12e
MMK-AT	4.2	3.9	6.3	5.8	10.9	10.7
CCL.B-CA					11.9	10.6
CAS-CA	6.4	5.0	20.8	11.1	94.4	9.1
GPK-US	6.4	5.4	12.7	9.8	13.4	10.2
SON-US	6.8	6.0	9.9	8.9	13.3	12.7
RKT-US	10.5	5.4	15.0	8.3	10.6	8.8
MWV-US	6.2	6.2	9.8	9.6	14.7	14.0
Median	6.4	5.4	11.3	9.3	13.3	10.6
CKL (FY12e/FY13e)	4.5	3.9	5.8	5.0	7.4	6.0
Variance	-29%	-28%	-49%	-46%	-44%	-43%

Source: Factset, CKL reports and estimates

Disclaimer and Disclosure of Interest

This document has been prepared by Pegasus Securities Pty Ltd. Whilst information contained in this publication has been prepared with all reasonable care from sources that Pegasus Securities believes are reliable, Pegasus Securities accepts no responsibility or liability for any errors, omissions or misstatements however caused. Any opinions, forecasts or recommendations reflects the judgment and assumptions of Pegasus Securities as at the date of publication and may change without notice.

This note is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. No representation or warranty, expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning Pegasus Securities, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the note. Recipients should not regard the note as a substitute for the exercise of their own judgment. Any opinions expressed in this note are subject to change without notice and may differ or be contrary to opinions expressed by other business areas within the Pegasus group as a result of using different assumptions and criteria. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analysts responsible for the preparation of this report may interact with other constituencies of the Pegasus group for the purpose of gathering, synthesizing and interpreting market information. Pegasus Securities is under no obligation to update or keep current the information contained herein. Pegasus Securities relies on information barriers to control the flow of information contained in one or more areas within the Pegasus group, in to other areas, units, groups or affiliates of Pegasus.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. Pegasus Securities nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report.

Distributed by Pegasus Securities Pty Ltd, Authorised Representative of Pegasus Corporate Advisory Pty Ltd (AFS Licence No 299 752) only to "Wholesale" clients as defined by s761G of the Corporations Act 2001.

All rights reserved. This report may not be reproduced or redistributed, in whole or in part, without the written permission of Pegasus Securities and Pegasus Securities accepts no liability whatsoever for the actions of third parties in this respect.

Pegasus Securities has been commissioned by Colopak Limited for the completion of this research report. Pegasus Securities currently holds no shares or options in any of the companies referred to in this report. This position is subject to change without notice.